Rewiring of regulatory networks by endogenous retroviruses

Information

  • Research Project
  • 10389698
  • ApplicationId
    10389698
  • Core Project Number
    R35GM128822
  • Full Project Number
    3R35GM128822-04S1
  • Serial Number
    128822
  • FOA Number
    PA-20-272
  • Sub Project Id
  • Project Start Date
    8/1/2018 - 5 years ago
  • Project End Date
    7/31/2023 - 11 months ago
  • Program Officer Name
    PHILLIPS, ANDRE W
  • Budget Start Date
    8/1/2021 - 2 years ago
  • Budget End Date
    7/31/2022 - a year ago
  • Fiscal Year
    2021
  • Support Year
    04
  • Suffix
    S1
  • Award Notice Date
    9/1/2021 - 2 years ago

Rewiring of regulatory networks by endogenous retroviruses

Project summary  Endogenous  retroviruses  (ERVs)  are  ubiquitous  genomic  parasites  originating  from  ancient  infectious  retroviruses,  and  constitute  8%  of  the  human  genome.  Large-­scale  genomic  studies  have  revealed  ERVs  as  major source of transcriptional regulatory elements in mammalian cells, suggestive of an extensive role in driving  the evolution of gene regulatory networks in both health and disease. However, the specific consequences and  biological significance of ERV regulatory activity remains controversial and not well understood. The proposed  research seeks to investigate emerging roles for ERVs in (1) the evolution of immune regulatory networks and  (2)  gene  dysregulation  in  cancer.  First,  we  will  investigate  a  potentially  fundamental  role  for  ERVs  driving  regulatory  evolution  of  innate  immune  responses  in  mammals,  through  genome-­wide  epigenetic  and  transcriptional profiling of the interferon response in cells derived from diverse mammalian species. This work is  positioned  to  uncover  a  recurrent  role  for  ERVs  in  regulating  immune  pathways,  which  may  reveal  pervasive  underappreciated  differences  in  immune  responses  across  species.  In  a  second  line  of  research,  we  seek  to  investigate how the epigenetic derepression of ERVs in cancer contributes to pathological gene expression. The  transcriptional  reactivation  of  ERVs  is  a  hallmark  of  many  cancers,  but  their  potential  contribution  to disease  remains  poorly  understood.  We  will  investigate  how  reactivated  ERVs  might  cause  widespread  regulatory  dysfunction  as  a  global  source  of  cancer-­specific  promoters,  enhancers,  and  noncoding  RNAs.  Focusing  on  colorectal cancer as a model, we will repurpose pooled CRISPR screening to investigate how reactivated ERVs  regulate  phenotypes  contributing  to  oncogenesis.  Our  interdisciplinary  approach  synthesizes  functional  genomics,  genome  engineering,  evolution,  and  disease  to  form  a  comprehensive  platform  for  deciphering  the  consequences of ERVs on mammalian biology.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R35
  • Administering IC
    GM
  • Application Type
    3
  • Direct Cost Amount
    125000
  • Indirect Cost Amount
  • Total Cost
    125000
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
    ORGANIZED RESEARCH UNITS
  • Funding ICs
    NIGMS:125000\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZGM1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    UNIVERSITY OF COLORADO
  • Organization Department
    MISCELLANEOUS
  • Organization DUNS
    007431505
  • Organization City
    Boulder
  • Organization State
    CO
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    803031058
  • Organization District
    UNITED STATES